Eli Lilly and’s (LLY) “Buy” Rating Reaffirmed at BMO Capital Markets
Several other equities research analysts also recently commented on LLY. SunTrust Banks Inc. reaffirmed a buy rating on shares of Eli Lilly and in a report on Wednesday, June 15th. Leerink Swann reaffirmed a buy rating on shares of Eli Lilly and in a report on Sunday, June 26th. Credit Suisse Group AG reiterated a buy rating on shares of Eli Lilly and in a research report on Tuesday, June 28th. Jefferies Group upped their price target on Eli Lilly and from $100.00 to $105.00 and gave the company a buy rating in a research report on Thursday, July 14th. Finally, Zacks Investment Research upgraded Eli Lilly and from a hold rating to a buy rating and set a $93.00 price target on the stock in a research report on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $97.16.
Eli Lilly and (NYSE:LLY) traded up 0.35% during midday trading on Monday, hitting $81.28. 139,918 shares of the stock were exchanged. The company’s 50 day moving average is $79.26 and its 200 day moving average is $77.27. Eli Lilly and has a 1-year low of $67.88 and a 1-year high of $88.16. The company has a market capitalization of $85.97 billion, a P/E ratio of 35.03 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. The business had revenue of $5.40 billion for the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The company’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.90 earnings per share. Analysts predict that Eli Lilly and will post $3.59 earnings per share for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 240,000 shares of the firm’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $82.87, for a total value of $19,888,800.00. Following the transaction, the insider now directly owns 126,020,570 shares of the company’s stock, valued at $10,443,324,635.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jackson P. Tai bought 2,560 shares of the company’s stock in a transaction on Friday, August 12th. The stock was purchased at an average cost of $80.42 per share, for a total transaction of $205,875.20. Following the completion of the transaction, the director now directly owns 42,110 shares of the company’s stock, valued at approximately $3,386,486.20. The disclosure for this purchase can be found here. 0.20% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Factory Mutual Insurance Co. boosted its position in shares of Eli Lilly and by 77.3% in the first quarter. Factory Mutual Insurance Co. now owns 448,300 shares of the company’s stock valued at $32,282,000 after buying an additional 195,500 shares during the last quarter. River Wealth Advisors LLC boosted its position in shares of Eli Lilly and by 17.8% in the first quarter. River Wealth Advisors LLC now owns 4,052 shares of the company’s stock valued at $292,000 after buying an additional 611 shares during the last quarter. Mn Services Vermogensbeheer B.V. purchased a new position in shares of Eli Lilly and during the first quarter valued at about $1,580,000. Virginia Retirement System purchased a new position in shares of Eli Lilly and during the first quarter valued at about $41,600,000. Finally, American Economic Planning Group Inc. ADV boosted its position in shares of Eli Lilly and by 7.4% in the first quarter. American Economic Planning Group Inc. ADV now owns 4,403 shares of the company’s stock valued at $317,000 after buying an additional 303 shares during the last quarter. 74.96% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.